LeMaitre Vascular (LMAT) Scheduled to Post Quarterly Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.02. The firm had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.25 EPS. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Trading Down 0.3 %

NASDAQ:LMAT opened at $64.03 on Thursday. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $74.64. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 47.78, a price-to-earnings-growth ratio of 2.70 and a beta of 0.87. The company’s 50-day moving average is $65.28 and its two-hundred day moving average is $58.01.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date was Wednesday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.14. LeMaitre Vascular’s payout ratio is currently 47.76%.

Analyst Upgrades and Downgrades

Several analysts have commented on LMAT shares. Barrington Research lifted their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, KeyCorp began coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating for the company. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.20.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,859 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $69.73, for a total transaction of $1,942,608.07. Following the completion of the sale, the chief executive officer now directly owns 2,255,737 shares of the company’s stock, valued at approximately $157,292,541.01. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO George W. Lemaitre sold 27,859 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $69.73, for a total transaction of $1,942,608.07. Following the transaction, the chief executive officer now directly owns 2,255,737 shares of the company’s stock, valued at $157,292,541.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John A. Roush sold 7,500 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at $157,182. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,036 shares of company stock valued at $7,873,749. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.